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Abstract: Despite the yearly global impact of influenza B viruses (IBVs), limited host range has been
a hurdle to developing a readily accessible small animal disease model for vaccine studies. Mouseadapting IBV can produce highly pathogenic viruses through serial lung passaging in mice. Previous
studies have highlighted amino acid changes throughout the viral genome correlating with increased
pathogenicity, but no consensus mutations have been determined. We aimed to show that growth
system can play a role in mouse-adapted IBV lethality. Two Yamagata-lineage IBVs were serially
passaged 10 times in mouse lungs before expansion in embryonated eggs or Madin–Darby canine
kidney cells (London line) for use in challenge studies. We observed that virus grown in embryonated
eggs was significantly more lethal in mice than the same virus grown in cell culture. Ten additional
serial lung passages of one strain again showed virus grown in eggs was more lethal than virus grown
in cells. Additionally, no mutations in the surface glycoprotein amino acid sequences correlated to
differences in lethality. Our results suggest growth system can influence lethality of mouse-adapted
IBVs after serial lung passaging. Further research can highlight improved mechanisms for developing
animal disease models for IBV vaccine research.
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1. Introduction

and Jishu Shi

Influenza viruses are respiratory pathogens that cause up to 5 million severe cases of
illness annually [1]. Influenza B viruses (IBVs), whose primary reservoir is humans [2,3],
are one of two types of influenza viruses that cause annual epidemics of varying severity [1].
IBVs are responsible for roughly 25% of all influenza cases on an annual basis, but seasonal
epidemics can approach or even surpass influenza A viruses (IAVs) in total and severe
infections [4–6]. IBVs are categorized into two antigenically and genetically distinct lineages,
B/Victoria- (B/Vic) and B/Yamagata-like (B/Yam) based on the surface glycoprotein,
hemagglutinin (HA). These lineages have cocirculated since the late 1970s or early 1980s [7]
and both cause infections each influenza season today.
IBVs have been shown to lead to significant disease just as severe as IAVs [8,9] and
often cause heightened disease burden in children [10,11]. In 2013–2014, a quadrivalent
influenza vaccine was recommended for yearly influenza vaccines in the US for increased
protection against IBV and is still recommended in the United States today [12]. Additionally, recent findings suggest that the two lineages are undergoing constant changes in their
antigenic epitopes, and B/Vic viruses experienced major antigenic changes in the hemagglutinin around 2018 [6,13–15]. The results from clinical, epidemiological, and evolutionary
research all point to the need for more attention on both molecular research and further
development of novel vaccine and therapeutic technologies to protect against IBV.
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Historically, influenza viruses have been grown in the allantoic fluid of embryonated
eggs as the primary vaccine production strategy [16,17]. However, the discovery of Madin–
Darby canine kidney (MDCK) cell susceptibility to influenza viruses [18] has further
opened studies into cell-culture-based vaccines [19–21]. Today, these two methods of virus
production are the most common methods for inactivated or live-attenuated vaccine development. However, IBVs are not consistently found infecting species outside humans [2,3],
which then requires adaptation of the viruses to develop a disease model for in vivo research. Scientists have used serial lung passaging, termed mouse-adapting, of virus to
study viral characteristics or to increase pathogenicity of IBVs [22–26] and IAVs [27–29] in
mice. Mouse-adapted strains are valuable for vaccine and therapeutic research by causing
severe infection, which can highlight differences in protection after vaccination or therapeutic delivery. However, this process is very time consuming and resource intensive.
Some studies reporting the mouse-adaptation of IBVs expanded the virus to high titer in
eggs [22,23]. Alternatively, many more recent reports of mouse-adapted IBVs opt to grow
the viruses in MDCK cell culture after passage in mice [24–26]. Amino acid mutations
from all eight viral gene segments have been associated with increased pathogenicity after
mouse-adapting [23–26], but none of the observed mutations were shared across these
studies. Further understanding of the characteristics leading to more lethal IBV infections
in mice will provide better tools for use in IBV vaccine and therapeutic research.
In this report, we set out to determine if the growth system of mouse-adapted IBVs
after serial lung passaging influences lethality in mice. We used two Yamagata-lineage
viruses, B/Phuket/3073/2013 and B/Florida/4/2006, as our parent viruses due to their
inclusion in previously licensed influenza vaccines. Interestingly, we found that after
10 serial lung-lung passages of both parent strains, virus expanded in eggs was more
lethal in BALB/c mice than the same virus expanded in MDCK (London line) (MDCK-Ln)
cell culture. This effect was also seen after additional passaging of B/Florida/4/2006,
even though the additional passaging did not further increase the lethality of the virus.
We further identified that the effect on lethality was not due to differences in surface
glycoprotein amino acid sequence of B/Florida/4/2006 due to no observed changes in
the hemagglutinin (HA) or neuraminidase (NA) protein sequence. Overall, these results
show that growing mouse-adapted B/Yam strains in eggs may produce virus with higher
lethality in mice than expansion in cell culture.
2. Materials and Methods
2.1. Cells and Virus Stocks
The following reagents used in this study were kindly provided by the International
Reagent Resource (IRR): influenza B virus B/Phuket/3073/2013 (Phu/13) [FR-1364] and the
Madin–Darby canine kidney cells, London line (MDCK-Ln) [FR-58]. The following virus
was kindly provided by the Biodefense and Emerging Infectious Disease Repository (BEI):
influenza B virus B/Florida/4/2006 (FL/4/06) [NR-9696]. Stock viruses obtained from
IRR and BEI were used to infect the allantoic cavity 10 or 11 day-old embryonated chicken
eggs (Charles River Laboratories, Wilmington, MA, USA) and incubated at 33–35 ◦ C.
Allantoic fluid was harvested 48–72 h after infection and virus was quantified through
hemagglutinating units (HAU), aliquoted, and stored at −80 ◦ C. Each virus was only
subjected to one round of growth in embryonated eggs after arrival from IRR or BEI.
MDCK-Ln cells were maintained in Dulbecco’s Modified Essential Medium (DMEM)
(Cytiva) supplemented with 5% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(P/S) (Cytiva) antibiotics and incubated at 37 ◦ C in 5% CO2 .
2.2. Mice
The 6–8 week old female BALB/cJ mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA). Mice were housed for experiments and general care at the University of Nebraska-Lincoln (UNL) Life Science Annex on campus according to the Association
for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines. The
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Figure1.1.Schematic
Schematic depicting
depicting mouse-passaging
mouse-passaging procedure.
Figure
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the
lung lysate. Passage 2 mice were then infected with 20 µ L of pooled lung lysate and the procedure
lung lysate. Passage 2 mice were then infected with 20 µL of pooled lung lysate and the procedure
was repeated up to passage 10. After homogenizing passage 10 lungs, the lysate was diluted and
was repeated up to passage 10. After homogenizing passage 10 lungs, the lysate was diluted and
used to infect either embryonated chicken eggs or MDCK-London cells. Infected embryonated eggs
used
infect either
chicken
eggs
or MDCK-London
cells.
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at 33 ◦ C before expansion into a 225 cm2 flask. Finally, 225 cm2 MDCK-London cells were incubated
at 33 ◦ C for 72 h before harvesting virus from supernatant. Schematic created in BioRender.
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2.5. Mouse-Adapted Virus Growth
Lung lysate from each virus was used to infect both 10–11-day old embryonated
chicken eggs and a 25 cm2 tissue-culture flask (Falcon) of MDCK-Ln cells. Infected eggs
were incubated at 33 ◦ C for 72 h before being placed at 4 ◦ C overnight. The next day,
allantoic fluid from each egg was harvested and HAU were quantified before storing at
−80 ◦ C. MDCK-Ln cells in a 25 cm2 flask with 2 µg/mL (0.002%) TPCK-treated trypsin in
the media were infected and incubated at 33 ◦ C with 5% CO2 for 48 h. Cell supernatant was
then collected and centrifuged in order to remove cell debris. The supernatant was used to
then infect a 75 cm2 tissue culture flask seeded with MDCK-Ln cells and incubated for 48 h
33 ◦ C with 5% CO2 . After 48 h, the supernatant was again collected and centrifuged before
infecting a 225 cm2 tissue culture flask of MDCK-Ln cells for 72 h before a final supernatant
harvest. All strains grown in MDCK-Ln cells were verified to have an HAU ≥ 256 before
harvest to ensure efficient virus production and cytopathic effects (CPE) were observed
during incubation at each sequential step. Virus from both eggs and cells were quantified
using HAU, aliquoted, and stored at −80 ◦ C until future use.
2.6. Tissue Culture Infectious Dose (TCID50 )
A total of 10 µL of virus was diluted 1:10 in the first row of a 96-well U-bottom
plate. The initial dilution was then serially diluted 10-fold down the plate. An amount of
1.5 × 105 MDCK-Ln cells in DMEM supplemented with 5% FBS without antibiotics were
then added into each well and the cell-virus mixture was incubated at 33 ◦ C with 5% CO2
for 24 h. After incubation, the plate was washed twice using DPBS to remove free virus
from the wells and 200 µL DMEM without FBS or antibiotics with 2 µg/mL TPCK-treated
trypsin was added to all the wells. The plates were then incubated for 72 h at 33 ◦ C with
5% CO2 before adding 50 µL of 0.5% cRBCs into each well. The agglutination patterns
were analyzed 45 min after addition of cRBCs [30]. TCID50 values were calculated using
the Reed–Muench method [31] and obtained from three independent experiments.
2.7. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was extracted from allantoic fluid or cell-free supernatant containing virus using
the PureLink Viral RNA/DNA Mini Kit (Invitrogen, Waltham, MA, USA) by following
the manufacturer’s recommendations. The viral RNA was then run through qPCR using
the Luna Universal Probe One-Step RT-qPCR Kit (New England Biolabs, Ipswich, MA,
USA) using the Universal Influenza B Primer Probe Set (BEI Resources, Manassas, VA,
USA) [NR-15608, NR-15609, NR-15610]. RT-PCR was performed using the QuantStudio
3 Real-Time PCR System (Applied Biosystems) with the following parameters: 55 ◦ C for
30 min, 95 ◦ C for 2 min, 95 ◦ C for 15 s, and 60 ◦ C for 15 s as recommended by BEI resources
for the influenza virus real-time RT-PCR assay. A total of 40 cycles were used to complete
amplification. IBV positive samples were identified by a Ct value difference of ≥10 cycles
above the no template control reactions.
2.8. Influenza Challenges
Upon anesthetization with K/X, female BALB/cJ mice (n = 5) were infected with
specified logTCID50 unit viral challenge in a 20 µL dose. Mice were then followed for
14 days post-infection to compare weight loss between groups or humanely sacrificed upon
loss of 25% initial weight. For parent virus infection (p0), allantoic fluid containing either
Phu/13 or FL/4/06 was diluted 1:2 in DPBS for challenge with a 1:100 dilution of the
TCID50 /mL previously calculated. For mouse-adapted viruses, dilutions were calculated
based off delivering 10-fold serial dilutions from 6log10 TCID50 to 3log10 TCID50 units in
20 µL doses.
2.9. RNA Isolation, Amplification and Sequencing
IBV RNA was generated from 200 µL of virus stock using the Qiagen RNeasy mini
kit (Cat: 74104). The RNA was eluted in RNA-free water and converted to cDNA by
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IBV RNA was generated from 200 µ L of virus stock using the Qiagen RNeasy 5mini
kit (Cat: 74104). The RNA was eluted in RNA-free water and converted to cDNA by onestep reverse transcription and PCR using a Superscipt III RT kit (Invitrogen; Cat:
one-step reverse
and PCR using
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L reaction master0 )mix,
0 ), 25 µL reaction master mix,
B-HANA-UniR
(50 -CGGGTTATTAGTAGTAACAAGAGC-3
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water, 5 µ L of RNA, and 2 µ L SSIII RT/Plat
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16
µLamplified
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and 2 µL
RT/Plat
Taq was combined.
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was
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the ProFlex
PCR system
bySSIII
Applied
Biosystems.
The HA and
NA
was
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by
Applied
Biosystems.
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HA
and
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amplified PCR product was gel extracted using the Qiagen Gel extraction kit (Cat: 28706)
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PCR
product
was
gel
extracted
using
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extraction
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and eluted in 40 µ L elution buffer. An amount of 2 µ L of cDNA was combined with 1 µ L
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in 40 (3.2
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B
specific
µ M) and
9 µ L water
and submitted
the St.was
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specific oligos
(3.2for
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for Sanger
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DNASTAR Ab1
Lasergene
15.
combined and analyzed with DNASTAR Lasergene 15.
2.10. Statistical Analysis
2.10. Statistical Analysis
GraphPad Prism v9 was used to complete all data analysis. Infectivity data shown
GraphPad Prism v9 was used to complete all data analysis. Infectivity data shown
represent averages of three biological replicates with the standard deviation between the
represent averages of three biological replicates with the standard deviation between
trials. In vivo challenge study data is the average of 5 mice included in each group. Error
the trials. In vivo challenge study data is the average of 5 mice included in each group.
bars represent the standard deviation at each data point. p values below 0.05 were considError bars represent the standard deviation at each data point. p values below 0.05 were
ered significant in this study. Statistical analysis of TCID50 titers was performed through
considered significant in this study. Statistical analysis of TCID50 titers was performed
multiple unpaired t-tests using two-tailed p values, and significant
differences in survival
through multiple unpaired t-tests using two-tailed p values, and significant differences in
were inferred using the log-rank Mantel–Cox to determine differences between groups (*
survival were inferred using the log-rank Mantel–Cox to determine differences between
p < 0.05, ** p < 0.01).
groups (* p < 0.05, ** p < 0.01).

3.
3. Results
Results
3.1. Lethality of Phu/13 and FL/4/06 in Mice Prior to Mouse-Adapting
Influenza viruses do not typically cause disease in mice. However, lethal challenge
strains of influenza are often optimal for vaccine
vaccine and
and therapeutics
therapeutics studies
studies [26,29,32–34].
[26,29,32–34].
Therefore, mouse-adapting is used to produce a disease model for use
in
laboratory
use in laboratory studstudies [23,26]. Before beginning the mouse-adapting process, we first needed to characterize
virus titers were
any pathogenicity these viruses
viruses already
already possessed
possessed in
inmice.
mice.TCID
TCID5050/mL
/mL virus
mice with
with aa 1:2 dilution of chorioallantoic
calculated before challenging female BALB/cJ
BALB/cJ mice
TCID5050units
unitsPhu/13
Phu/13oror5log
5log1010
TCID
units
FL/4/06
a
fluid containing either 3.5log10
10TCID
TCID
50 50
units
FL/4/06
in ain20
20LµL
dose
(Figure
2A).
This
was
themaximum
maximuminfectious
infectiousdose
doseofofeach
eachvirus
virus that
that could
could be
µ
dose
(Figure
2A).
This
was
the
delivered. Weight loss was monitored for 14 days after infection (Figure 2B). No signs of
meaningful weight loss were detected in the two weeks post-challenge with the maximum
amount of virus able to be used prior to mouse-adaptation.
mouse-adaptation.
A

B

Figure 2. Live challenge with wild-type B/Florida/4/2006 and B/Phuket/3073/2013. (A) TCID50
values for each strain used for initial passage infection. Values shown are an average of three
independent experiments with error bars representing standard deviation between three independent
replicates. Statistical significance was determined through unpaired t-test, ** p < 0.01; (B) Weight loss
over 14 days shown after i.n. infection with 1:2 dilution of allantoic fluid of each parent virus. A ≥ 25%
initial weight lost (dotted line) was used as a threshold for humane sacrifice of the animals.
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To increase lethality for use in challenge studies, serial lung-passaging of these viruses
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was performed. A detailed schematic is shown (Figure 1). Direct lung-lung passages were
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Figure 3. Determination of pathogenicity of maB/Yam in mice. (A) TCID50/mL titers of both strains

Figure
3. 10
Determination
of pathogenicity
in mice. eggs
(A) TCID
/mL
titers ofcell
both strains
after
lung-lung passages
and expandedofinmaB/Yam
either embryonated
(p10E)50or
MDCK-Ln
after 10 lung-lung passages and expanded in either embryonated eggs (p10E) or MDCK-Ln cell
culture (p10C). (B) Table breaking down MLD50 values calculated using the Reed–Meunch method
(31) for each virus strain. (C) Mice challenged with doses corresponding to logTCID50 of FL/4/06
p10E or p10C were followed for 14 d.p.i. for weight loss (top) and survival after challenge with 5log
TCID50 units (bottom). A ≥25% initial weight lost was used as a threshold for humane sacrifice of
the animals. (D) Mice challenged with doses corresponding to logTCID50 of Phu/13 p10E or p10C
were followed for 14 d.p.i. for weight loss (top) and survival after challenge with 5log TCID50 units
(bottom). A ≥25% initial weight lost was used as a threshold for humane sacrifice of the animals.
Statistical differences in TCID50 /mL titers were calculated using unpaired t-tests, while statistical
significance between group survival was calculated through log-rank Mantel–Cox test. Statistical
analysis was performed in GraphPad Prism 9.0 (* p < 0.05, ** p < 0.01).
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Groups of five mice were challenged with p10E or p10C from either strain using the
same TCID50 unit dose to determine if either expansion media conferred higher mortality
in vivo. Each group was infected with a serial 10-fold dilution starting from 6log10 TCID50
units and were monitored for weight loss and mortality. A table of the median lethal dose
(MLD50 ) values calculated with the Reed–Muench method [31] is provided (Figure 3B). The
full weight loss graph for each MLD50 is provided (Figure 3C,D). Groups are presented
based on whether the virus was grown in eggs (p10E) or in cells (p10C) and the log10
TCID50 challenge dose. Weight loss was much more drastic in mice infected with p10E
strains down to as low as a 5log10 TCID50 unit dose when compared with virus grown in
cells. Similar weight loss was observed between p10E and p10C of both FL/06 and Phu/13
at a 4log10 TCID50 unit dose, below our calculated MLD50 values. When we focused on the
5log10 TCID50 unit dose, we observed a significant difference in lethality of both FL/06 and
Phu/13 p10E when compared to p10C (Figure 3C,D). Together, these results show after
10 serial passages of two different strains of B/Yam, amplification of virally infected lung
lysate in eggs produced a significantly more lethal virus in mice compared to the same
lung lysate amplified in cell culture.
3.3. Infectivity In Vitro and Lethality in Mice of FL/4/06 after 10 Additional Passages
We also set out to see what role additional passaging may play on one of our strain’s
virulence and if it supports our observations from 10 direct lung-lung passages. To do this,
the FL/4/06 p10E virus was used to complete another round of 10 lung-lung passages as
described above. The egg-passaged virus was chosen due to its higher initial pathogenicity
in mice. After an additional 10 passages, the homogenized lung lysate was used to infect
embryonated eggs and MDCK-Ln cell culture for viral expansion. TCID50 /mL values were
once again confirmed and used for dosing in the challenges. Again, FL/4/06 p20E grew to
a higher infectious titer in MDCK-Ln cell culture than p20C (Figure 4A).
The challenge doses used for p20E and p20C were identical infectious titers to p10E and
p10C. MLD50 calculations were repeated using the p20 strains (Figure 4B). Again, the postinfection weight loss and survival curves (Figure 4C) show that the p20E viruses maintained
lethality significantly better after expansion than p20C viruses. Significant weight loss
was observed by day 8 in mice infected with the highest doses of p20E while no severe
weight loss was observed in mice infected with any dose of p20C. In the 6 log10 TCID50
dose, infection with p20E led to significantly more mortality than infection with p20C
(Figure 4C). These results corroborate what was seen after 10 passages of both FL/06
and Phu/13. Interestingly, neither p20E nor p20C viruses increased in lethality after
10 additional passages as measured through MLD50 titers (Figures 3B and 4B). Differences
in survival between p10E and p20E were not significant (Figure 4D). This is especially
notable because FL/06 p10E was used to start the further 10 passages, and no significant
weight loss or lethality was observed after the virus was grown in MDCK-Ln cells. This
highlights the potential for further study to understand why this cell culture system is not
conducive to the growth of mouse lethal IBV strains.
3.4. Sequence Analysis of FL/4/06 HA and NA before and after Mouse-Adapting
To attempt to find any genetic mutations responsible for the lethality differences observed between the parental and mouse-adapted viruses, we sequenced the HA and NA
genes of FL/4/06. We chose to sequence this virus since it had been serially passaged
20 total times in mice. We observed that the HA and NA of the p10 and p20 FL/4/06 were
identical to the parental virus irrespective of growth system. The four major antigenic sites
of the influenza B virus HA are shown (Figure 5A) [35]. The only identifiable difference
observed after sequencing was a single nucleotide mutation in the HA sequence (Figure 5B).
However, this mutation was silent and did not change the amino acid sequence. The complete HA amino acid and nucleotide sequence alignments are shown in Figures S1 and S2,
respectively. A representative NA amino acid sequence alignment from positions 161–320
is shown (Figure 5C). All amino acid sequences were identical to the parental virus prior to
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Figure 4. Pathogenicity of FL/4/06 after 20 total lung-lung passages. (A) TCID50 /mL titers of
p20E and p20C. (B) Table breaking down MLD50 values calculated using the Reed–Meunch method
FL/4/06 p20E and p20C. (B) Table breaking down MLD50 values calculated using the Reed–Meunch
(31) for FL/4/06 p20E and p20C. (C) Mice challenged with doses corresponding to logTCID50 of
method (31) for FL/4/06 p20E and p20C. (C) Mice challenged with doses corresponding to logTCID50
FL/4/06 p20E or p20C were followed for 14 d.p.i. for weight loss (top) and survival after challenge
of FL/4/06 p20E or p20C were followed for 14 d.p.i. for weight loss (top) and survival after challenge
with 6log TCID50 units (bottom). A ≥25% initial weight lost was used as a threshold for humane
with 6log TCID50 units (bottom). A ≥25% initial weight lost was used as a threshold for humane
sacrifice of the animals. (D) Comparison of survival probability of mice challenged with 5log TCID50
the animals.
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3.4. Sequence Analysis of FL/4/06 HA and NA before and after Mouse-Adapting
To attempt to find any genetic mutations responsible for the lethality differences observed between the parental and mouse-adapted viruses, we sequenced the HA and NA
genes of FL/4/06. We chose to sequence this virus since it had been serially passaged 20
total times in mice. We observed that the HA and NA of the p10 and p20 FL/4/06 were
identical to the parental virus irrespective of growth system. The four major antigenic sites
of the influenza B virus HA are shown (Figure 5A) [35]. The only identifiable difference
observed after sequencing was a single nucleotide mutation in the HA sequence (Figure
5B). However, this mutation was silent and did not change the amino acid sequence. The
complete HA amino acid and nucleotide sequence alignments are shown in Figures S1
and S2, respectively. A representative NA amino acid sequence alignment from positions
161–320 is shown (Figure 5C). All amino acid sequences were identical to the parental
virus prior to mouse-adapting. The full-length NA amino acid and nucleotide alignments

Viruses 2022, 14, x
Viruses 2022, 14, 1299

9 of 13
9 of 13

Figure
surfaceglycoprotein
glycoprotein
sequence
analysis.
genes
reverse
Figure5.5.FL/4/06
FL/4/06 surface
sequence
analysis.
TheThe
HAHA
andand
NA NA
genes
werewere
reverse
transcribed intointo
cDNA,
PCR
amplified,
andand
sequenced
using
Sanger
sequencing.
(A) The
antitranscribed
cDNA,
PCR
amplified,
sequenced
using
Sanger
sequencing.
(A) major
The major
genic sites
[35]
of of
the
HA
The single
single
antigenic
sites
[35]
the
HAprotein
proteinare
areshown
showntotobe
beidentical
identicalto
to the
the parental
parental virus.
virus. (B)
(B) The
nucleotidemutation
mutation
observed
between
parental
virus
the mouse-adapted
HA sequences
nucleotide
observed
between
thethe
parental
virus
andand
the mouse-adapted
HA sequences
was
was a single silent mutation between nucleotide 241 and 320. (C) A representative amino acid aligna single silent mutation between nucleotide 241 and 320. (C) A representative amino acid alignment
ment of the NA protein from positions 161–320 shows 100% sequence conservation between the
of the NA protein from positions 161–320 shows 100% sequence conservation between the parental
parental and the mouse-adapted viruses.
and the mouse-adapted viruses.

Discussion
4.4.Discussion
InfluenzaBBviruses
virusesare
arerelevant
relevantrespiratory
respiratorypathogens
pathogensthat
thatcause
cause significant
significant disease
disease
Influenza
burden
each
year
around
the
globe
[1,4–6].
Despite
this,
the
inability
to
naturally
cause
burden each year around the globe [1,4–6]. Despite this, the inability to naturally cause
infections
in
many
mouse
strains
has
led
to
difficulty
of
developing
easily
accessible
small
infections in many mouse strains has led to difficulty of developing easily accessible
animal
disease
models
for IBV
and therapeutic
research.
The process
of mousesmall
animal
disease
models
forvaccine
IBV vaccine
and therapeutic
research.
The process
of
adapting
IBV
has
been
used
to
define
in
vivo
pathogenic
determinants
[24–26]
andand
for
mouse-adapting IBV has been used to define in vivo pathogenic determinants [24–26]
development
of lethal
strains
for use
vaccine
and therapeutics
studies
[32–34,36].
Howfor
development
of lethal
strains
for in
use
in vaccine
and therapeutics
studies
[32–34,36].
ever,
performing
mouse-adapting
series
can
be
costly
and
may
not
produce
consistent
or
However, performing mouse-adapting series can be costly and may not produce consistent
repeatable
results.
Differing
genetic
determinants
of
pathogenicity
studies
in
the
BALB/c
or repeatable results. Differing genetic determinants of pathogenicity studies in the BALB/c
mousemodel
model
[23–26]
also
contribute
a lack
of consistency
between
procedures.
mouse
[23–26]
also
cancan
contribute
to ato
lack
of consistency
between
procedures.
Thus,
Thus, development
of aavailable
widely available
reverse system
geneticsfor
system
for generating
lethal
videvelopment
of a widely
reverse genetics
generating
lethal viruses
such
ruses
such
as
those
for
IAV
[37,38]
is
less
feasible.
Recognizing
these
issues
with
the
as those for IAV [37,38] is less feasible. Recognizing these issues with the mouse-adapting
mouse-adapting
process,
we designed
this study
to investigate
whether
setting
process,
we designed
this study
to investigate
whether
growth setting
cangrowth
influence
the
can
influence
the
lethality
of
IBV
after
serial
lung-lung
passaging
in
mice
(Figure
1).
lethality of IBV after serial lung-lung passaging in mice (Figure 1).
Ourresults
resultssuggest
suggestthat
thatviral
viralgrowth
growthsystem
systemmay
mayplay
play aa role
role in
in mouse-adapted
mouse-adapted IBV
IBV
Our
lethality.Having
Havingbeen
beeninitially
initiallygrown
growninineggs,
eggs,the
theparent
parentvirus
virusstrains
strains showed
showed no
no lethality
lethality
lethality.
miceover
overtwo
twoweeks
weeksofofinfection
infection(Figure
(Figure2).
2).These
Theseviruses
viruseswere
were then
then passaged
passaged 10
10 times
times
ininmice
miceasasdescribed
describedabove
aboveand
andamplified
amplifiedin
inboth
bothembryonated
embryonatedeggs
eggs and
and MDCK-Ln
MDCK-Ln cells
cells
ininmice
for
further
study.
A
total
of
10
initial
passages
were
chosen
based
on
previous
studies
in
for further study. A total of 10 initial passages were chosen based on previous studies in
which
mouse-adapted
strains
of
IBV
[23]
as
well
as
various
IAV
subtypes
were
deemed
which mouse-adapted strains of IBV [23] as well as various IAV subtypes were deemed
sufficienttotoincrease
increaselethality
lethalityofofthe
theviruses
viruses[39,40].
[39,40].This
This was
was also
also performed
performed more recently
sufficient
forswine
swineinfluenza
influenzaH1
H1viruses
viruses[41].
[41]. Since
Since 10
10 passages
passages is
is often
often fewer
fewer than
than is
is required
required to
to
for
mouse-adaptIBV
IBV[24–26],
[24–26],this
thisserved
servedas
asour
ourbenchmark
benchmark for
for potential
potential improvement
improvement on
on
mouse-adapt
establishedmethods
methodsfrom
fromthe
theliterature.
literature. Our
Our model
model also
also eliminated
eliminated any
any intermediate
intermediate
established
growthsteps
stepsininembryonated
embryonated
eggs
MDCK-Ln
culture
in between
passages.
growth
eggs
or or
MDCK-Ln
cellcell
culture
in between
lunglung
passages.
We
believed that this may improve pathogenicity at the end after viral growth by maximizing

Viruses 2022, 14, 1299

10 of 13

the amount of time spent in mouse lung tissue and preventing any mutations driven by
replication in other systems.
As a proxy for overall pathogenicity, we determined the median lethal dose for the
p10 mouse-adapted B/Yam strains grown in eggs and cells. Mice were challenged with
equivalent TCID50 units of each virus (Figure 3). These mice were followed 14 days for
weight loss and survival (Figure 3C,D), and the MLD50 was calculated (Figure 3B). We
observed that expanding the final passage lung lysate in eggs led to increased weight
loss and significantly lower chance of survival than expansion in MDCK-Ln cell culture
for both B/Yam strains. While not often considered in research studies, preparation of
mouse-adapted B/Yam stocks appears to play a role in the lethality of these viruses in mice.
To further support our findings, we took one of the two lethal mouse-adapted B/Yam
strains and completed a further round of 10 serial lung-lung passages. FL/4/06 p10E was
chosen as the initial strain for infection due to its higher initial lethality seen in mice. After
20 total lung-lung passages, the final lung lysate was once again used to infect embryonated
eggs or MDCK-Ln cell culture. Infectious titers were obtained in vitro (Figure 4A) and used
to calculate challenge doses in mice. Once again, at the same infectious dose, FL/4/06
p20E led to increased weight loss and decreased chance of survival when compared to
p20C (Figure 4C). Interestingly, neither p20E nor p20C were able to increase the level of
lethality in mice as measured by the MLD50 titer compared to p10E, the strain used to start
further mouse-adapting. While the difference in lethality of p10E and p20E was found to be
insignificant (Figure 4D), p20C appeared to lose almost all lethality even after 10 additional
passages. This was an unexpected result, but it is possible that the mutations needed to
further increase the lethality did not occur in the 10 additional passages. It is also possible
that the intermediate egg growth interfered with the ability of these mutations to occur.
Additionally, we saw no amino acid mutations in either of the surface glycoproteins even
after 20 total serial lung passages. Previous studies have identified mutations across many
of the different gene segments, but internal gene mutations are often shown to have the
most critical effect on viral pathogenicity [23,24,26]. Further sequencing of the entire viral
genome will help elucidate exactly what mutations occurred in our model.
MDCK-Ln cells were chosen for this study due to the increased growth rate and reported increased susceptibility to influenza virus infection with the ability to produce virus
at a higher titer than MDCK cells [42,43]. While these strains have both previously been
incorporated as influenza vaccine strains, two representative strains may not represent
all the diversity in the Yamagata-lineage. More work is required to determine if this phenomenon is shared not only among other strains of B/Yam, but also of B/Vic and ancestral
IBV. Another consideration to make is the presence of defective-interfering particles. These
particles have been shown to play active roles in modulating host immune responses while
also inhibiting replication of normal infectious particles [44]. Our serial lung-lung passage
model is unable to rule out production of these particles or highlight what role they could
play in the process if these particles are present.
It is also important to recognize egg growth of IBV may not be appropriate for certain
studies. Both IBV and IAV have been shown to undergo mutations in the HA which shift
receptor-binding capability towards embryonated eggs and away from human epithelial
tissue by passaging [45,46]. These egg-adapted mutations also have been shown to alter the
antigenicity of the viruses [47]. However, our viral glycoprotein sequence analysis showed
that even over 20 lung passages as well as expansion steps in embryonated eggs and/or
cell culture, no further mutations occurred in either the HA or NA. This would suggest
the single expansion step did not introduce any egg-adaptation mutations after serial lung
passaging. This could be impactful for some vaccine development studies to show limited
development of egg-adapted mutations using single replication steps rather than repeated
egg passage over time. Additionally, if growth of virus in eggs was responsible for lethality,
we would have expected to see some mortality in our parent strain challenge at a high
concentration of egg-grown virus (Figure 2B). This leads us to conclude that the serial
lung-lung passaging played the primary role in the lethality we observed.
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In this study, our preliminary findings support that influenza B virus pathogenicity in
mice may not require adaptation in the surface glycoproteins to increase lethality. While
our results cannot rule out internal gene mutations, any genetic differences between virus
grown in eggs and virus grown in cell culture would have been influenced by the growth
systems. These different settings appear to be capable of influencing the in vivo lethality
of mouse-adapted IBV. Further research with our model will better characterize this phenomenon and assist in overcoming a major hurdle in the influenza vaccine and therapeutic
research field. By increasing the availability of better disease models, we hope to assist in
the development of more suitable tools to study this important disease.
5. Conclusions
Influenza B viruses are primarily a human pathogen. While known to cause a significant portion of annual influenza infections and severe disease, development of mouse
disease models has historically been difficult and inconsistent. We aimed to identify if the
growth system of viral expansion after mouse-adapting influences lethality when used in
mouse challenge studies. We used two Yamagata-lineage strains for our mouse-adapting
model. Our results show that at the same in vitro infectious dose, virus grown in embryonated eggs is significantly more lethal than the same virus grown in MDCK-Ln cell culture.
The differences in lethality between virus grown in eggs and cell culture was not due to
amino acid changes in the surface glycoprotein sequences. Further studies will aim to
identify the mechanism which drives these differences in lethality.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/v14061299/s1, Figure S1. Hemagglutinin amino acid sequence alignment of B/Florida/06, Figure S2. Hemagglutinin nucleotide sequence alignment of B/Florida/06,
Figure S3. Neuraminidase amino acid sequence alignment of B/Florida/06, Figure S4. Neuraminidase
nucleotide sequence alignment of B/Florida/06.
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